|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||28.18 - 28.79|
|52-week range||28.18 - 28.79|
|Beta (5Y monthly)||1.71|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Market forces rained on the parade of bluebird bio, Inc. ( NASDAQ:BLUE ) shareholders today, when the analysts...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020, inclusive (the "Class Period") of the important April 13, 2021 lead plaintiff deadline.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.